| HS Code | 420263 |
| Product Name | Bufonis Venenum Veterinary Grade API |
| Api Name | Bufonis Venenum (Toad Venom Extract) |
| Veterinary Grade | Yes |
| Intended Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Active Components | Bufadienolides (e.g., Cinobufagin, Resibufogenin) |
| Appearance | Brownish-yellow to brown powder |
| Solubility | Slightly soluble in water; soluble in ethanol and dilute alkali |
| Assay Bufadienolides | ≥ 20% by HPLC |
| Loss On Drying | ≤ 5.0% |
| Heavy Metals | ≤ 20 ppm |
| Microbial Limits | Complies with veterinary pharmacopoeia standards |
| Storage Conditions | Cool, dry, airtight container, protected from light |
| Shelf Life | 24 months when stored properly |
As an accredited Bufonis Venenum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Sealed, light-protected, tamper-evident drums of 25 kg net each, ensuring stability and purity of Bufonis Venenum veterinary grade API. |
| Container Loading (20′ FCL) | Bufonis Venenum Veterinary Grade API packed in sealed drums, palletized and loaded into 20′ FCL containers for secure, contamination-free transport. |
| Shipping | Ship in sealed, light-resistant, moisture-proof containers with clear hazardous-material labeling per international regulations. Use temperature-controlled, dry freight to preserve potency. Include Safety Data Sheet, Certificate of Analysis, and origin documentation. Secure drums or pouches to prevent breakage; ship via experienced air or sea freight forwarder for veterinary pharmaceutical ingredients. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature (below 25°C), protected from light and moisture. Keep in tightly sealed original containers, away from incompatible substances, direct sunlight, and heat sources. Follow pharmacopoeial guidelines for veterinary APIs; expiry and handling precautions apply. |
| Shelf Life | Shelf life: 36 months when stored in original, sealed containers, protected from light and moisture, at controlled room temperature. |
Formulation of Bufonis Venenum into a sterile injectable solution for food-producing species begins with selection of a standardized dry extract rather than raw dried secretion; the unrefined secretion carries mucoprotein aggregates and insoluble bufotoxin-protein conjugates that raise bioburden and reduce filterability through 0.22 µm sterilising membranes. The compliance frame for this dosage form includes EU Regulation 2019/6 for veterinary medicinal products, EudraLex Volume 4 Annex 1 for sterile manufacture, monograph methods of the Chinese Veterinary Pharmacopoeia (2020 edition) for assay of total bufadienolides and related bufalin, cinobufagin, and resibufogenin markers, and VICH GL18 for residual solvent control in the starting extract. Because the API is standardised to total bufadienolides rather than a fixed weight of raw secretion, the addition ratio is calculated from the approved species-specific dose per kilogram and the extract assay; a representative stock solution uses 0.10%–0.50% w/v dry extract in water for injection, with the fill volume established during product development and not as a universal percentage. Processing on a licensed sterile line proceeds by dissolving the extract in a phosphate-buffered water-for-injection vehicle at 45±2 °C and pH 6.2–6.8, followed by 0.45 µm pre-filtration and 0.22 µm sterilising filtration into depyrogenated glass vials under Grade A laminar flow. Terminal steam sterilisation at 121 °C for 15 min requires a forced-degradation study because the six-membered bufadienolide lactone ring is susceptible to alkaline hydrolysis in condensed steam; published comparative data for this specific extract configuration are limited, so aseptic filtration is the conservative manufacturing route. On multi-head aseptic filling lines, hold time after final filtration should not exceed 4 h without revalidation. Finished terminal products include single-dose and multi-dose vials of 10 mL, 20 mL, and 50 mL for porcine, bovine, and ovine parenteral administration under veterinary prescription.
Direct compression of Bufonis Venenum dry extract is constrained less by the bufadienolide assay than by the extract’s hygroscopicity and caking tendency above 65% relative humidity; compression failures on single-punch and rotary presses commonly appear as sticking to upper punches, capping at low-dose core edges, and weight variation caused by hopper bridging. Release and stability standards for tablets include Ph. Eur. 2.9.40 for uniformity of dosage units, Ph. Eur. 2.9.1 for disintegration, the Chinese Veterinary Pharmacopoeia (2020 edition) for assay and related substances, and manufacturing compliance aligned with EU Regulation 2019/6 and 21 CFR 211. A typical low-dose tablet core uses 1.0%–5.0% w/w dry extract, yielding 3–15 mg extract in a 300 mg core; the final dose of total bufadienolides is adjusted through the extract assay during product development. The downstream process employs wet granulation rather than direct compression: the extract is pre-dried at 45–50 °C to loss on drying below 2.5%, dispersed in a povidone K30 binder solution at 3.0% w/w solids, granulated through a 1.0 mm screen, dried in a fluid-bed dryer with inlet air at 55–60 °C and product temperature not exceeding 40 °C, lubricated with 0.5% w/w magnesium stearate, and compressed at 8–15 kN on a rotary press with forced feeder speed below 40 rpm. Pre-drying at RH > 60% is mandatory before blending; magnesium stearate above 0.5% w/w should be avoided because the apolar coating retards disintegration of hygroscopic granules. Terminal finished products are round or oblong oral tablets in bottle and blister configurations for companion mammals and ex-situ managed ungulates where prescribed by a veterinarian.
Fill-weight drift in hard capsules containing Bufonis Venenum dry extract usually originates from electrostatic charge accumulation on lactose monohydrate after 30–45 min blending in low-humidity conditions, not from assay-related losses; the charge effect produces dosator underfill and increases weight variability when the fill mass is below 200 mg. Compliance for capsule release includes Ph. Eur. 2.9.40 for dose uniformity, Ph. Eur. 2.9.3 or USP 711 for dissolution, and stability storage under VICH GL3; API assay and related substances follow the Chinese Veterinary Pharmacopoeia (2020 edition). A 200 mg hard capsule fill contains 2.0%–4.0% w/w dry extract, giving 4–8 mg extract per capsule; dose-per-unit is determined by the total bufadienolide assay rather than raw extract weight. The downstream process pre-sieves the extract through 180 µm, blends in a bin blender at 12 rpm for 30 min at 30–40% RH, and fills with dosator pins adjusted to ±3% of target weight; fill moisture is controlled below 4.0%. If gelatine capsules are used, equilibrium moisture above 6.0% can cause shell embrittlement; HPMC capsules are preferred for storage in Zone IVb. Published dissolution data for this exact dry-extract capsule configuration are limited, so surfactant addition to the dissolution medium must be justified in the filing; 0.1–0.5% w/w sodium lauryl sulfate may be used if the bufadienolide aglycones show poor media wetting at 37±0.5 °C and paddle speed 50 rpm. Terminal finished products include size 0 and size 1 hard capsules for companion-animal pharmacy dispensing, with child-resistant packaging when the product is intended for home administration.
Drinking-water reconstitution of Bufonis Venenum dry extract requires a carrier system that prevents irreversible agglomeration of bufadienolide aglycones when the finished powder contacts cold water at 10–20 °C; dry blends of extract and coarse lactose crystals frequently settle within 3 min and produce uneven gavage exposure under field mixing. Release compliance includes Ph. Eur. 2.9.36 powder flow, Ph. Eur. 2.9.12 sieve analysis, and the Chinese Veterinary Pharmacopoeia (2020 edition) for content uniformity of single-dose preparations; if the product is marketed as a veterinary medicinal powder, EU Regulation 2019/6 applies, whereas feed-hygiene obligations under Regulation (EC) 183/2005 apply to mill-level handling. The addition ratio is 0.05%–0.30% w/w dry extract on a lactose-maltodextrin carrier for the concentrated powder, reconstituted at 0.5–1.0 g powder per litre of drinking water to deliver the prescribed daily dose. The downstream process uses fluid-bed top-spray granulation with inlet air at 60–65 °C, product temperature maintained below 40 °C, atomising pressure 2.5 bar, and final moisture below 3.0%; the granulated powder is sieved to 100–500 µm to achieve resuspendability within 3 min under 500 rpm orbital shaking. Dry blending without granulation is not recommended because the API extract segregates from coarse carrier crystals at a coefficient of variation above 5%. Finished terminal products are water-soluble powders and granules in 100 g, 500 g, and 1 kg sachets for poultry and swine drinking-water administration.
When a 0.5% w/w Bufonis Venenum concentrated premix is diluted into final compound feed, the release criterion shifts from extract assay alone to mixer coefficient of variation and carry-over control, because active particles must remain attached to the carrier during screw conveying, bucket elevator transfer, and pneumatic delivery into finish bins. The applicable compliance standards are EU Regulation 2019/4 on medicated feed, Regulation (EC) 183/2005 on feed hygiene, and EU Regulation 2019/6 for the veterinary medicinal product component; assays for total bufadienolides follow the Chinese Veterinary Pharmacopoeia (2020 edition), method validation is aligned with VICH GL2, and sampling follows ISO 6497. The concentrated premix contains 0.5%–2.0% w/w dry extract on ground rice hulls or corncob meal; final feed inclusion is 0.05%–0.20% w/w, requiring stepwise dilution from a 10% intermediate premix to final feed. Downstream processing uses a ribbon blender with primary mixing at 30 rpm for 15 min, secondary mixing at 30 rpm for 10 min after addition of 0.2% w/w vegetable oil as de-dusting and segregation suppressant; carrier particle-size range is 100–800 µm, and mixer coefficient of variation must remain below 5.0% based on 10 thief samples. Elevator transfer after final mixing should be minimised, and carrier moisture must be pre-dried below 6.0% before charging because moisture migration from corncob carriers above 10% loads the extract and promotes caking. Finished terminal products include medicated premix bags of 5 kg, 10 kg, and 25 kg for feed-mill dilution into swine and poultry compound feed.
Oral solutions for neonatal ruminants introduce a different set of process boundaries: the solubility of bufadienolide aglycones in water is pH-dependent, and aggregation at pH below 5.0 can generate visible precipitation during refrigerated storage at 4–8 °C. The compliance framework includes Ph. Eur. 2.2.3 pH measurement, stability testing under VICH GL3, and jurisdictional approval under EU Regulation 2019/6 when the solution is placed on the market as a veterinary medicinal product. The oral solution contains 0.02%–0.10% w/v dry extract in a co-solvent system of propylene glycol 10–20% v/v and ethanol 2–4% v/v, with the balance purified water; final pH is adjusted to 6.4–6.8 with citrate buffer. A 100 mL solution at 0.05% w/v delivers 50 mg dry extract per bottle, and the dose per kilogram is set by the prescribing veterinarian from the extract’s bufadienolide assay. Manufacturing uses a covered stainless-steel vessel; the extract is dissolved in propylene glycol at 40±2 °C, ethanol is incorporated, then purified water is added under low-light conditions, and the solution is passed through 1 µm clarifying filters before filling into amber Type III glass bottles with tamper-evident closures. Strong reducing agents such as sodium metabisulfite should be avoided because bufadienolides may undergo reduction at the unsaturated lactone; pH values above 7.5 accelerate base-catalysed hydrolysis. Terminal finished products include 100 mL, 250 mL, and 500 mL oral solutions for calves, lambs, and goat kids, with withdrawal periods determined under EU Regulation 2019/6 before food-producing use.
Competitive Bufonis Venenum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Bufonis Venenum Veterinary Grade API, commercial model code BVN-VG-6.0, is a standardized dried secretion of Bufo bufo gargarizas Cantor or Bufo melanostictus Schneider processed under veterinary GMP conditions. The model designation 6.0 refers to the minimum total bufadienolide content of the released material expressed as cinobufagin at 6.0% w/w. The API is intended as the active substance for tablets, injections, capsules, powders, granules, premix carriers, and oral solutions; it is not a finished veterinary product. The material is supplied as an amorphous powder with characteristic colour and odour, packed in double polyethylene-lined HDPE drums with desiccant. Because Bufonis Venenum contains a complex array of bufadienolide glycosides and aglycones, including bufalin, cinobufagin, and resibufogenin, this material is not interchangeable with isolated chemical markers or with crude toad venom. The product is released against a multi-attribute specification that includes assay, chromatographic identity, moisture, residue on ignition, heavy metals, residual solvents, and microbial limits.
The release specification addresses both pharmacopoeial identity and processability across solid, semi-solid, and liquid dosage forms. The powder is pale yellow to greyish-brown and is freely soluble in ethanol and methanol, sparingly soluble in propylene glycol, and practically insoluble in water. The aqueous insolubility is a critical parameter for parenteral formulation, as it requires co-solvent or surfactant-based approaches rather than simple reconstitution in water for injection. Loss on drying is controlled to ≤ 5.0% by USP <731>; higher moisture values increase the risk of particle fusion during milling and reduce flowability in dry powder blending. Residue on ignition is limited to ≤ 1.0% by USP <281>. Heavy metals are controlled to ≤ 10 ppm, with routine release performed by ICP-MS according to USP <233> or a validated equivalent. The total aerobic microbial count is ≤ 1000 CFU/g, and Escherichia coli is absent in 1 g by USP <62>. Residual solvents are tested by headspace gas chromatography according to USP <467>; only Class 3 solvents are used in processing, and Class 2 solvents must be below the stated limits.
| Parameter | Release specification | Test method |
|---|---|---|
| Description | Pale yellow to greyish-brown amorphous powder | Visual |
| Identification | TLC positive for bufalin, cinobufagin, resibufogenin | ChP 2020 |
| Assay total bufadienolides | ≥ 6.0% w/w expressed as cinobufagin | HPLC, UV 296 nm |
| Loss on drying | ≤ 5.0% | USP <731> |
| Residue on ignition | ≤ 1.0% | USP <281> |
| Heavy metals | ≤ 10 ppm | ICP-MS USP <233> |
| Total aerobic microbial count | ≤ 1000 CFU/g | USP <61> |
| Escherichia coli | Absent in 1 g | USP <62> |
| Particle size standard grade | ≥ 90% below 150 µm | Laser diffraction ISO 13320:2009 |
| Particle size micronized grade | ≥ 90% below 25 µm | Laser diffraction ISO 13320:2009 |
| Residual solvents | Class 2 solvents within USP <467> limits | Headspace GC |
Particle size is offered in two grades. The standard grade is used for granules, premixes, and dry powders. The micronized grade is intended for suspension formulations and for dry blends requiring high content uniformity. The HPLC assay for total bufadienolides uses a C18 column, a gradient of acetonitrile and 0.1% phosphoric acid, and UV detection at 296 nm. Marker identification is performed by thin-layer chromatography against bufalin, cinobufagin, and resibufogenin reference standards. The total bufadienolide content is expressed as cinobufagin because cinobufagin is a consistent major component; marker ratios may vary with natural source and season and should be monitored during formulation development.
Compatibility across tablets, capsules, and granules is governed less by the chemical identity of the bufadienolides than by the cohesiveness and low bulk density of the unprocessed powder. Direct compression is generally not recommended because the raw API exhibits poor flow and high segregation potential. Wet granulation is preferred. In a pilot-scale high-shear mixer with impeller speeds of 200 rpm to 400 rpm and chopper speeds of 1500 rpm to 3000 rpm, the API is granulated with microcrystalline cellulose, povidone, and purified water to a target endpoint moisture of 2.0% to 3.0%. The wet mass is dried in a fluid-bed dryer at inlet air temperature not exceeding 60 °C and milled through a 0.8 mm screen. Tablets are compressed to hardness 60 N to 120 N and friability below 1.0% by USP <1216>. For capsules, the milled API is blended with lactose monohydrate and magnesium stearate in a V-blender; content uniformity is targeted at 90% to 110% of label claim with RSD not more than 5.0% by USP <905>. Because the API has an unpleasant taste and potential irritant effect on gastric mucosa, coated tablets or hard capsules are preferable when oral dosage forms are used in companion animals. Published data for specific therapeutic indications in companion animals is limited; dose range and safety must be established for the target species.
Three forms of Bufonis Venenum-derived material are commonly encountered in veterinary formulation development, and they are not equivalent. Crude toad venom is the dried secretion without extraction or standardization; its total bufadienolide content ranges widely with geographic origin, season, and species, and its microbial load is often uncontrolled. The veterinary-grade API is a processed extract that has undergone dissolution, filtration, concentration, and blending to a defined total bufadienolide content. Isolated bufalin or cinobufagin is a single chemical entity, typically with purity above 98.0%, and does not reproduce the full bufadienolide matrix present in the natural secretion. The full matrix may influence solubility, partitioning, and stability of the dosage form; therefore, substitution of isolated chemical markers for the standardized API is not permitted without revalidation.
The veterinary-grade product also differs in documentation and impurity control. It is released with a certificate of analysis containing batch number, manufacture date, retest date, assay, moisture, residue on ignition, heavy metals, residual solvents, particle size, and microbial limits. Crude venom purchased from non-GMP collectors rarely includes this documentation. The API is tested against USP <61>, USP <62>, and USP <467>, whereas unstandardized extracts may carry non-specified bacterial endotoxins or residual organic solvents.
| Attribute | Crude toad venom | Veterinary-grade API BVN-VG-6.0 | Isolated bufalin |
|---|---|---|---|
| Standardization | Not standardized; total bufadienolides variable | Total bufadienolides ≥ 6.0% expressed as cinobufagin | Single entity, purity ≥ 98.0% |
| Microbial control | Generally uncontrolled | USP <61>/<62> limits | Not applicable |
| Particle size | Unprocessed, irregular | Standard ≤ 150 µm; micronized ≤ 25 µm | Crystalline or lyophilized |
| Residual solvents | Uncontrolled | USP <467> tested | Supplier CoA |
| Suitability for multi-dosage forms | Requires in-house extraction and clean-up | Direct use in tablets, capsules, powders, granules, premix, solutions, injections with pre-treatment | Reference standard or derivatization; not full matrix |
Powder and premix production requires segregation control because the API has significantly higher density than some feed carriers and tends to settle. The recommended procedure is geometric dilution with calcium carbonate or colloidal silicon dioxide prior to mixing in a ribbon blender or ploughshare mixer. Premix concentrations of 0.1% to 1.0% API by weight are typical for subsequent let-down into feed; the acceptance limit for active content in the finished premix is ± 10% of labelled amount. The powder should be stored in tight containers at controlled room temperature under nitrogen or vacuum-sealed foil, because prolonged exposure to humidity above 60% relative humidity may cause discoloration and particle caking. If the premix is intended for feed pelleting, the API should be added post-pelleting or the pellet die temperature should not exceed 70 °C, because heat-induced degradation of minor bufadienolide components requires evaluation; published kinetic data for this specific configuration is limited.
Injectable formulations of Bufonis Venenum Veterinary Grade API present a recognizably different development challenge from solid oral forms. The API is practically insoluble in water; therefore, parenteral solutions are prepared by dissolving the powder in a co-solvent system comprising propylene glycol and ethanol in water for injection. A representative solubilisation vehicle contains 10% to 30% v/v propylene glycol and 5% to 15% v/v ethanol, with final pH adjusted to 5.5 to 6.5. If the formulation is intended for multiple-dose containers, an antimicrobial preservative must be added, but its compatibility with bufadienolides should be confirmed because phenolic preservatives may interact with unsaturated lactone rings. The bulk solution is prefiltered through a 0.45 µm membrane and then sterilized by filtration through a 0.22 µm sterilizing-grade filter. Aseptic filling is mandatory unless a terminal sterilisation cycle has been validated; if terminal sterilisation is used, the product must be tested for degradation products because bufadienolides contain heat-sensitive functional groups.
Bacterial endotoxin control for veterinary injectables should be established per the target species and route, typically not more than 0.5 EU/mg of API for parenteral use, but this value must be justified by the finished product specification. The API manufacturer can provide a low-endotoxin grade with additional processing controls, but depyrogenation of natural extract material is not straightforward and may require ultrafiltration or chromatographic purification. Filter integrity testing by bubble point or forward-flow method is required for each sterilizing-grade filter assembly. The maximum hold time between sterile filtration and filling should be validated; unpreserved bulk solution should not be held for more than 24 h at 2 °C to 8 °C unless supporting data are available.
Oral solutions prepared from this API generally require the same co-solvent approach but do not require sterilizing filtration. A typical oral solution is prepared by dissolving the API in a mixture of propylene glycol and ethanol, then diluting with flavoured vehicle to a final concentration of 0.1 mg/mL to 1.0 mg/mL total bufadienolides. The solution pH is maintained between 5.0 and 6.5; above pH 8.0, bufadienolide esters may undergo accelerated hydrolysis, and below pH 3.0, acid-catalysed degradation of glycosidic linkages is possible. The finished solution should be filled into amber glass or high-density polyethylene bottles with tight closures and protected from light. Because the API contains multiple bufadienolide components, a stability-indicating HPLC method should be developed and validated for the specific preservation system; the parent API method may not resolve preservative peaks.
Lot-to-lot variation in natural Bufonis Venenum is a known operational boundary. The veterinary-grade API is blended from multiple extraction batches to reduce the total bufadienolide variation to a defined release band; however, single-marker ratios cannot be fixed as tightly as synthetic chemicals. Formulators should establish internal acceptance windows for marker ratios—not simply total assay—when the bioactivity or stability of the dosage form is sensitive to individual components. A lot-to-lot total assay variation of ± 10% relative to label claim is typical for natural product APIs; if tighter control is required for narrow therapeutic index veterinary drugs, the formulator should commission a dedicated production campaign with reserve samples from the same collected season. The manufacturer’s certificate of analysis includes a chromatographic profile and marker ratio. The routine release HPLC method may not separate all minor bufadienolides; therefore, an orthogonal UPLC-qTOF method is recommended for full profiling when developing injections for target species with unknown metabolism.
Because of the potent pharmacologic activity of bufadienolides, handling of the API requires containment. Bufadienolides are cardioactive; skin contact, inhalation, and accidental oral exposure must be prevented. Manufacturing operators should handle the powder in a downflow booth or isolator with local exhaust ventilation and wear nitrile gloves, protective clothing, and respiratory protection if dust is generated. A health-based exposure limit has not been formally established in public guidance; therefore, containment should be based on the principle that the material is a potent cardioactive natural product. Any spill should be collected with a HEPA-filtered vacuum and residues wiped with water and detergent, not dry-swept. Use in food-producing animals requires residue depletion and withdrawal period data for the specific formulation; this API does not include finished product approval.
